Delphian Therapeutics Revenue
Biotechnology Research • 
222 Merchandise Mart Plaza, 1230, United States • 1-10 Employees
Delphian Therapeutics revenue & valuation
| Annual revenue | $598,885 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | No funding |
Key Contact at Delphian Therapeutics
George Pappas
Chief Executive Officer
Company overview
| Headquarters | 222 Merchandise Mart Plaza, 1230, Chicago, Illinois 60654, US |
| Website | |
| NAICS | 541714 |
| Employees | 1-10 |
| Socials |
About Delphian Therapeutics
Optimized Endocannabinoid System targeting for FDA-approval in large pain and central nervous system disorders, with a lead indication in migraine, one of the world's most debilitating, most poorly managed diseases, afflicting over 1 billion people worldwide. The ECS is a a vast network of ligands and proteins and high-level regulator of multiple biological systems. Highly selective CB1 or CB2 targeting holds limited promise to modulate the system to its full therapeutic potential. Instead, ECS modulation is optimized by targeting multiple sites at once, using compounds that have extremely well-established safety profiles. Delphian is funded in part by the Migraine Research Foundation and the U.S. National Institutes of Health.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Delphian Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Delphian Therapeutics has never raised funding before.
Italy
China
Australia
Canada
Portugal
United Kingdom
Frequently asked questions
4.8
40,000 users
